Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

HOLLY L HAKE HARRIS

Allopathic & Osteopathic Physicians Dermatology

NPI
1538159207
CMS profile
890706
Location
SOUTH BEND, IN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$60.71

3 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $60.71 3

By paying entity

PY2025 · entire year · sorted by reported total

Paying entityAmountRecords
ABBVIE INC. $24.01 1
GENZYME CORPORATION $19.62 1
Lilly USA, LLC $17.08 1

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

HOLLY L HAKE HARRIS

NPI 1538159207 · CMS profile ID 890706

Allopathic & Osteopathic Physicians / Dermatology

SOUTH BEND, IN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1538159207?year=2025&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
HOLLY L HAKE HARRIS, NPI 1538159207, CMS profile ID 890706. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1538159207?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). HOLLY L HAKE HARRIS, NPI 1538159207, CMS profile ID 890706. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1538159207?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
HOLLY L HAKE HARRIS, NPI 1538159207, CMS profile ID 890706, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1538159207?year=2025&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

3 matching records · $60.71 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 3 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–3 of 3.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ABBVIE INC. $24.0107/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201991368 CMS
GENZYME CORPORATION $19.6204/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233695767 CMS
Lilly USA, LLC $17.0804/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186600368 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,931.99 7
PY2021 $29.68 2
PY2022 $77.19 4
PY2023 $448.39 16
PY2024 $189.69 8
PY2025 $60.71 3

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $2,042.82 1
PY2025 Principal investigator $214,389.75 98
PY2024 Recipient $6,347.66 1
PY2024 Principal investigator $293,318.73 162
PY2023 Principal investigator $348,782.35 197
PY2022 Recipient $100.00 2
PY2022 Principal investigator $164,469.18 81
PY2021 Principal investigator $449,676.56 73
PY2020 Recipient $15,456.30 2
PY2020 Principal investigator $642,662.67 80
PY2019 Recipient $418,491.34 8
PY2019 Principal investigator $1,194,399.32 72

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

163 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PFIZER INC. $1,696.02 12/25/2024 Non-covered Recipient Entity
Qcare Site Services Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1130968744
Principal investigator 1 PFIZER INC. $24,325.74 12/05/2024 Non-covered Recipient Entity
Qcare Site Services Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1130968738
Principal investigator 1 Incyte Corporation $1,526.00 11/20/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720791
Principal investigator 1 Incyte Corporation $2,077.00 11/20/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720807
Principal investigator 1 Incyte Corporation $2,289.00 11/20/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720827
Principal investigator 1 Incyte Corporation $2,289.00 11/20/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720829
Principal investigator 1 Incyte Corporation $2,289.00 11/20/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720831
Principal investigator 1 ABBVIE INC. $140.00 11/07/2024 Non-covered Recipient Entity
SOUTH BEND CLINIC LLP
Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema) No dispute reported 06/30/2026 1100754149
Principal investigator 1 PFIZER INC. $157.32 11/05/2024 Non-covered Recipient Entity
Qcare Site Services Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1130987471
Principal investigator 1 Incyte Corporation $11.90 11/04/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720799
Principal investigator 1 Incyte Corporation $95.90 11/04/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720801
Principal investigator 1 Incyte Corporation $34.40 11/04/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720803
Principal investigator 1 Incyte Corporation $95.90 11/04/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720805
Principal investigator 1 Incyte Corporation $1,973.20 10/18/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720789
Principal investigator 1 Incyte Corporation $540.00 10/16/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720785
Principal investigator 1 Incyte Corporation $8,655.30 10/16/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1134720787
Principal investigator 1 Incyte Corporation $47.50 10/02/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720793
Principal investigator 1 Incyte Corporation $32.00 10/02/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720795
Principal investigator 1 Incyte Corporation $2.00 10/02/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720797
Principal investigator 1 Incyte Corporation $84.50 10/02/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720819
Principal investigator 1 Incyte Corporation $2,289.00 09/25/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720765
Principal investigator 1 Incyte Corporation $1,518.40 09/25/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720767
Principal investigator 1 Incyte Corporation $2,440.00 09/25/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720823
Principal investigator 1 Incyte Corporation $2,289.00 09/25/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720841
Principal investigator 1 Incyte Corporation $2,077.00 09/25/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720877
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $26.00 09/04/2024 Non-covered Recipient Entity
Qcare Site Services Inc
Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis (POETYK PSO-LTE) No dispute reported 06/30/2026 1123479345
Principal investigator 1 Incyte Corporation $33.54 09/04/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720735
Principal investigator 1 Incyte Corporation $16.65 09/04/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720737
Principal investigator 1 Incyte Corporation $34.35 09/04/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720739
Principal investigator 1 Incyte Corporation $35.61 09/04/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720743
Principal investigator 1 Incyte Corporation $48.68 09/04/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720749
Principal investigator 1 Incyte Corporation $50.31 09/04/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720751
Principal investigator 1 Incyte Corporation $23.74 09/04/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720839
Recipient E.R. Squibb & Sons, L.L.C. $6,347.66 08/30/2024 Covered Recipient Physician Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis (POETYK PSO-LTE) No dispute reported 06/30/2026 1123481992
Principal investigator 1 Incyte Corporation $2,077.00 08/26/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720731
Principal investigator 1 Incyte Corporation $1,869.30 08/26/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720777
Principal investigator 1 PFIZER INC. $7,110.60 08/23/2024 Non-covered Recipient Entity
Qcare Site Services Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1131031433
Principal investigator 1 ABBVIE INC. $311.50 08/01/2024 Non-covered Recipient Entity
SOUTH BEND CLINIC LLP
Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema) No dispute reported 06/30/2026 1100733520
Principal investigator 1 Incyte Corporation $270.00 07/26/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720613
Principal investigator 1 Incyte Corporation $416.00 07/26/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720705
Principal investigator 1 Incyte Corporation $360.00 07/26/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720711
Principal investigator 1 Incyte Corporation $54.00 07/26/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720713
Principal investigator 1 Incyte Corporation $40.00 07/26/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720715
Principal investigator 1 Incyte Corporation $119.00 07/26/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720719
Principal investigator 1 Incyte Corporation $150.00 07/26/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720721
Principal investigator 1 Incyte Corporation $315.00 07/26/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720723
Principal investigator 1 Incyte Corporation $1,500.00 07/26/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720725
Principal investigator 1 Incyte Corporation $1,071.00 07/26/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720727
Principal investigator 1 Incyte Corporation $375.00 07/26/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720729
Principal investigator 1 Incyte Corporation $684.00 07/26/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720733
Principal investigator 1 Incyte Corporation $2,000.00 07/26/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720741
Principal investigator 1 Incyte Corporation $1,750.00 07/26/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720761
Principal investigator 1 Incyte Corporation $94.00 07/26/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720763
Principal investigator 1 Incyte Corporation $1,750.00 07/26/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720769
Principal investigator 1 Incyte Corporation $150.00 07/26/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720775
Principal investigator 1 Incyte Corporation $119.00 07/26/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720783
Principal investigator 1 Incyte Corporation $35.00 07/26/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720835
Principal investigator 1 Incyte Corporation $1,656.00 07/26/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720859
Principal investigator 1 Incyte Corporation $550.00 07/26/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720873
Principal investigator 1 Incyte Corporation $216.00 07/26/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720887
Principal investigator 1 Incyte Corporation $2,775.00 07/22/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720709
Principal investigator 1 Incyte Corporation $2,077.00 07/22/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720717
Principal investigator 1 Incyte Corporation $1,504.75 07/22/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720781
Principal investigator 1 Incyte Corporation $2,289.00 07/22/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720825
Principal investigator 1 Incyte Corporation $2,227.00 07/22/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720869
Principal investigator 1 Incyte Corporation $11.10 07/02/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720745
Principal investigator 1 Incyte Corporation $20.40 07/02/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720747
Principal investigator 1 Incyte Corporation $23.74 07/02/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720753
Principal investigator 1 Incyte Corporation $29.32 07/02/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720755
Principal investigator 1 Incyte Corporation $50.31 07/02/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720757
Principal investigator 1 Incyte Corporation $33.54 07/02/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720759
Principal investigator 1 Incyte Corporation $23.74 07/02/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720771
Principal investigator 1 Incyte Corporation $76.84 07/02/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720833
Principal investigator 1 Incyte Corporation $12.20 07/02/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720849
Principal investigator 1 Incyte Corporation $33.54 07/02/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720865
Principal investigator 1 Incyte Corporation $33.54 07/02/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720867
Principal investigator 1 Incyte Corporation $2,077.00 07/01/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720617
Principal investigator 1 Incyte Corporation $2,289.00 07/01/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720707
Principal investigator 1 Incyte Corporation $2,077.00 07/01/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720773
Principal investigator 1 Incyte Corporation $1,081.85 07/01/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720779
Principal investigator 1 Incyte Corporation $3,300.00 07/01/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720815
Principal investigator 1 Incyte Corporation $3,300.00 07/01/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720817
Principal investigator 1 Incyte Corporation $2,343.00 07/01/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720843
Principal investigator 1 Incyte Corporation $2,440.00 07/01/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720881
Principal investigator 1 Acrotech Biopharma Inc. $5,006.34 06/27/2024 Non-covered Recipient Entity
QCARE SITE SERVICES INC
MEDI-MM36-302 No dispute reported 06/30/2026 1147108090
Principal investigator 1 Incyte Corporation $140.00 06/10/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720665
Principal investigator 1 Incyte Corporation $476.00 06/10/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720669
Principal investigator 1 Incyte Corporation $180.00 06/10/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720671
Principal investigator 1 Incyte Corporation $170.00 06/10/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720837
Principal investigator 1 Incyte Corporation $162.00 06/10/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720853
Principal investigator 1 Incyte Corporation $125.00 06/10/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720855
Principal investigator 1 Incyte Corporation $11.87 06/04/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720655
Principal investigator 1 Incyte Corporation $63.96 06/04/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720657
Principal investigator 1 Incyte Corporation $33.54 06/04/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720659
Principal investigator 1 Incyte Corporation $23.74 06/04/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720661
Principal investigator 1 Incyte Corporation $5.94 06/04/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720663
Principal investigator 1 Incyte Corporation $76.84 06/04/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720847
Principal investigator 1 Incyte Corporation $31.98 06/04/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720871
Principal investigator 1 PFIZER INC. $1,544.40 06/04/2024 Non-covered Recipient Entity
Qcare Site Services Inc
A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1131059182
Principal investigator 1 PFIZER INC. $14,133.00 06/01/2024 Non-covered Recipient Entity
Qcare Site Services Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1131068207
Principal investigator 1 Acrotech Biopharma Inc. $2,400.00 05/15/2024 Non-covered Recipient Entity
QCARE SITE SERVICES INC
MEDI-MM36-302 No dispute reported 06/30/2026 1147107990
Principal investigator 1 Incyte Corporation $2,077.00 05/15/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720685
Principal investigator 1 Incyte Corporation $1,869.30 05/15/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720695
Principal investigator 1 ABBVIE INC. $1,486.70 05/08/2024 Non-covered Recipient Entity
SOUTH BEND CLINIC LLP
Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema) No dispute reported 06/30/2026 1100716138
Principal investigator 1 PFIZER INC. $1,544.40 05/03/2024 Non-covered Recipient Entity
Qcare Site Services Inc
A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1131076446
Principal investigator 1 Incyte Corporation $1.02 05/02/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720647
Principal investigator 1 Incyte Corporation $2,000.00 05/01/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1134720645
Principal investigator 1 Incyte Corporation $1,750.00 05/01/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1134720681
Principal investigator 1 Incyte Corporation $1,200.00 05/01/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1134720687
Principal investigator 1 Incyte Corporation $1,500.00 05/01/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1134720691
Principal investigator 1 Incyte Corporation $1,200.00 05/01/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1134720703
Principal investigator 1 Incyte Corporation $488.00 05/01/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1134720851
Principal investigator 1 Incyte Corporation $80.00 05/01/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis No dispute reported 06/30/2026 1134720861
Principal investigator 1 Incyte Corporation $2,077.00 04/22/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720683
Principal investigator 1 Incyte Corporation $2,227.00 04/22/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720689
Principal investigator 1 Incyte Corporation $2,289.00 04/22/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720693
Principal investigator 1 Incyte Corporation $1,425.20 04/22/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720697
Principal investigator 1 Incyte Corporation $2,077.00 04/22/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720699
Principal investigator 1 Incyte Corporation $2,289.00 04/22/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720879
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $5,482.62 04/19/2024 Non-covered Recipient Entity
Iqvia
Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis (POETYK PSO-LTE) No dispute reported 06/30/2026 1123477823
Principal investigator 1 PFIZER INC. $1,686.10 04/05/2024 Non-covered Recipient Entity
Qcare Site Services Inc
A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1131076381
Principal investigator 1 ABBVIE INC. $311.50 04/04/2024 Non-covered Recipient Entity
SOUTH BEND CLINIC LLP
Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema) No dispute reported 06/30/2026 1100711342
Principal investigator 1 Incyte Corporation $45.80 04/02/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720649
Principal investigator 1 Incyte Corporation $11.87 04/02/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720651
Principal investigator 1 Incyte Corporation $23.74 04/02/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720653
Principal investigator 1 Incyte Corporation $476.00 04/01/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720619
Principal investigator 1 Incyte Corporation $340.00 04/01/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720621
Principal investigator 1 Incyte Corporation $140.00 04/01/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720623
Principal investigator 1 Incyte Corporation $162.00 04/01/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720625
Principal investigator 1 Incyte Corporation $104.00 04/01/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720667
Principal investigator 1 Incyte Corporation $75.00 04/01/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720673
Principal investigator 1 Incyte Corporation $105.00 04/01/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720675
Principal investigator 1 Incyte Corporation $119.00 04/01/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720677
Principal investigator 1 Incyte Corporation $54.00 04/01/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720679
Principal investigator 1 Incyte Corporation $119.00 04/01/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720701
Principal investigator 1 Incyte Corporation $276.00 04/01/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720809
Principal investigator 1 Incyte Corporation $94.00 04/01/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720811
Principal investigator 1 Incyte Corporation $94.00 04/01/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720813
Principal investigator 1 Incyte Corporation $357.00 04/01/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720821
Principal investigator 1 Incyte Corporation $110.00 04/01/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720875
Principal investigator 1 Incyte Corporation $90.00 04/01/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720885
Principal investigator 1 Acrotech Biopharma Inc. $18,748.80 03/28/2024 Non-covered Recipient Entity
QCARE SITE SERVICES INC
246-13651-302 No dispute reported 06/30/2026 1147107906
Principal investigator 1 Incyte Corporation $2,077.00 03/25/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720635
Principal investigator 1 Incyte Corporation $1,957.00 03/25/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720637
Principal investigator 1 Incyte Corporation $3,300.00 03/25/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720883
Principal investigator 1 ABBVIE INC. $1,038.00 03/14/2024 Non-covered Recipient Entity
SOUTH BEND CLINIC LLP
Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema) No dispute reported 06/30/2026 1100708423
Principal investigator 1 PFIZER INC. $250.00 03/07/2024 Non-covered Recipient Entity
SOUTH BEND CLINICAL RESEARCH
A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD WITH RANDOMIZED DOSE UPDOSE DOWN TITRATION INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF RITLECITINIB IN ADULT PARTICIPANTS WITH NONSEGMENTAL VITILIGO No dispute reported 06/30/2026 1131087641
Principal investigator 1 Incyte Corporation $47.48 03/04/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720627
Principal investigator 1 Incyte Corporation $31.98 03/04/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720629
Principal investigator 1 Incyte Corporation $33.54 03/04/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720631
Principal investigator 1 Incyte Corporation $50.31 03/04/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720633
Principal investigator 1 Incyte Corporation $1.98 03/04/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720845
Principal investigator 1 Incyte Corporation $2,077.00 02/21/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720615
Principal investigator 1 Incyte Corporation $2,077.00 02/21/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720639
Principal investigator 1 Incyte Corporation $2,440.00 02/21/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720641
Principal investigator 1 Incyte Corporation $2,289.00 02/21/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720643
Principal investigator 1 Incyte Corporation $2,077.00 02/21/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720857
Principal investigator 1 Incyte Corporation $1,425.15 02/21/2024 Non-covered Recipient Entity
THE SOUTH BEND CLINIC MAIN CAMPUS
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, EfficacyAnd Safety of Ruxolitinib Cream in Participants with Prurigo Nodularis No dispute reported 06/30/2026 1134720863
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $13,544.39 01/26/2024 Non-covered Recipient Entity
Qcare Site Services Inc
Long-Term Study That Measures the Safety and Efficacy of BMS-986165 in Participants With Psoriasis No dispute reported 06/30/2026 1123479343
Principal investigator 1 Acrotech Biopharma Inc. $2,677.75 01/11/2024 Non-covered Recipient Entity
QCARE SITE SERVICES INC
246-13651-301 No dispute reported 06/30/2026 1147107672
Principal investigator 1 ABBVIE INC. $1,425.60 01/10/2024 Non-covered Recipient Entity
SOUTH BEND CLINIC LLP
Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema) No dispute reported 06/30/2026 1100699851
Principal investigator 1 Eli Lilly and Company $57,348.26 01/09/2024 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS (PK) OF BARICITINIB IN CHILDREN FROM 6 YEARS TO LESS THAN 18 YEARS OF AGE WITH ALOPECIA AREATA No dispute reported 06/30/2026 1137365629
Principal investigator 1 PFIZER INC. $1,544.40 01/09/2024 Non-covered Recipient Entity
Qcare Site Services Inc
A PHASE 3 MULTICENTER LONGTERM EXTENSION STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ABROCITINIB WITH OR WITHOUT TOPICAL MEDICATIONS ADMINISTERED TO SUBJECTS AGED 12 YEARS AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS No dispute reported 06/30/2026 1131076387

Ownership and Investment Interests

One row per program year and measure, newest year first · the amount invested and the value of the interest are never added together

Program yearMeasureAmountRecords
PY2025 Amount invested $0.00 1
PY2025 Value of interest $109,356.47 1
PY2024 Amount invested $2,443.72 1
PY2024 Value of interest $109,356.47 1
PY2023 Amount invested $0.00 1
PY2023 Value of interest $106,912.75 1
PY2022 Amount invested $0.00 1
PY2022 Value of interest $154,320.92 1
PY2021 Amount invested $0.00 1
PY2021 Value of interest $88,340.48 1
PY2020 Amount invested $0.00 1
PY2020 Value of interest $80,642.76 1
PY2019 Amount invested $80,595.00 1
PY2019 Value of interest $806,985.00 1

Ownership and Investment Interests are a separate CMS dataset, shown here separately and never added to payments.

Ownership and investment interests are reported as the value of an interest held, not as a payment received. They are a different measure from the payment total on this page and are never combined with it.

Ownership and Investment Interests records

Ordering applied by this site (program year, newest first, then company) · record values are shown as CMS published them

7 records · PY2019–2025

Ownership and Investment Interests records (CSV)

Program yearCompanyAmount invested Value of interestTerms of interestInterest held by Dispute statusPublishedRecord ID
PY2025 Digital Diagnostics Inc. $0.00 $109,356.47 Shares Owned by Immediate Family (Ben Clark) Immediate family member No dispute reported 06/30/2026 1254605365
PY2024 Digital Diagnostics Inc. $2,443.72 $109,356.47 Shares Owned by Immediate Family Immediate family member No dispute reported 06/30/2026 1153967797
PY2023 Digital Diagnostics Inc. $0.00 $106,912.75 Shares Owned by Immediate Family Immediate family member No dispute reported 06/30/2026 1060331987
PY2022 Digital Diagnostics Inc. $0.00 $154,320.92 Shares Owned by Immediate Family Immediate family member No dispute reported 06/30/2026 961154523
PY2021 Digital Diagnostics Inc. $0.00 $88,340.48 Shares Owned by Immediate Family Immediate family member No dispute reported 06/30/2026 855625849
PY2020 Digital Diagnostics Inc. $0.00 $80,642.76 Shares Owned by Immediate Family Immediate family member No dispute reported 06/30/2026 737170185
PY2019 IDx Technologies Inc. $80,595.00 $806,985.00 Shares Owned by Immediate Family Immediate family member No dispute reported 06/30/2026 676471935